VEGF/VEGFR monoclonal antibodies (e.g., bevacizumab and ramucirumab) and TKIs (e.g., orafenib, sunitinib and L = lenvatinib) not only suppress tumor vascular growth but also enhance immune infiltration and responsiveness to immunotherapy in HCC [74,103,104,105,135,136]. Here, VEGFA is linked to neoplasm.